Magazine April 3, 2017, Issue

Available Drugs, Affordable Drugs

President Donald Trump speaks during a meeting with pharmaceutical-industry leaders in the Roosevelt Room of the White House, January 31, 2017. (AP Photo/Evan Vucci)
A prescription for the new FDA commissioner

Over the past several months, President Trump has given the biotech industry a preview of the grand bargain he expects from it: It will accept more U.S.-based manufacturing and lower drug prices for government programs, in return for tax reform that would benefit the industry, tougher trade deals that would better protect U.S. biotech patents (in Canada, China, and elsewhere), improved market access in the U.K. and in Germany and other EU countries, and, most important, streamlined Food and Drug Administration regulations.

His broadsides against the industry, both during the 2016 campaign and after his November 8 victory, have left executives

To Read the Full Story

In This Issue



Books, Arts & Manners

Politics & Policy

Glittering Prizes

The disaster that overtook this year’s Oscar telecast in its closing moments, like so many strange events of the last two years, seemed almost scripted in its wild implausibility.


Politics & Policy


The Limits of Proportional Representation One must wrestle with two related issues when discussing gerrymandering: (1) If a state is divided 60–40 between Party A and Party B, and its ten neatly ...
Politics & Policy

The Week

‐ He pounds his chest, he roars, he perches on high-profile Manhattan real estate, and he can only be tamed by a clever blonde lady: Who could have seen this ...
Politics & Policy


THE APOTHEOSIS OF DON JUNE Promiscuous as moonlight on sand, He pondered heaven by the foaming surf; And staring at its brilliant text he saw He’d never been voluptuous enough. There were so many things ...


The Latest